Litigation
Jazz Pharmaceuticals, Inc. v. Par Pharmaceuticals, Inc.
settled2:13-cv-07884
Auto-generating section 1 of 4: Case overview & background…
Each section takes ~30-60s with web-search grounding. Keep this tab open — sections will fill in below as they complete.
- Court
- D.N.J.
- Filed
- 2013-12-27
- Terminated
- 2018-01-09
Patents at issue (1)
Plaintiffs (1)
Defendants (1)
Summary
ANDA Hatch-Waxman action by Jazz Pharmaceuticals against Par Pharmaceuticals involving Xyrem and US 7,765,107. Par's Paragraph IV notice was dated November 20, 2013; the case later settled on January 9, 2018 with an authorized-generic license.
Case overview & background
Plain-language overview of the case: parties, accused product, patents at issue, and why the suit matters.
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Key legal developments & outcome
Major rulings, motions, claim construction, settlements, and the present posture or final disposition.
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Plaintiff representatives
Counsel of record for the plaintiff(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Defendant representatives
Counsel of record for the defendant(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).